HAP Trading’s Travere Therapeutics TVTX Stock Holding History

HAP Trading’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-52,767	Closed	-$974K	–	1160
2017 Q1	$974K	Buy	+52,767	New	+$1.03M	0.06%	235

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

HAP Trading's TVTX Position: Q2 2017 in Review

HAP Trading sold out of Travere Therapeutics (TVTX) in Q2 2017, closing a stake of 52,767 shares — an estimated $974K sold.

HAP Trading first reported a position in TVTX in Q1 2017 and held it in 1 quarter. The position peaked at $974K in Q1 2017. 108 funds tracked by Wall St. Rank hold TVTX as of Q2 2017.

HAP Trading reported no remaining Travere Therapeutics position as of Q2 2017 after selling out during the quarter.
HAP Trading sold 52,767 Travere Therapeutics shares in Q2 2017, an estimated $974K.
HAP Trading first reported a position in Travere Therapeutics in Q1 2017 and held it in 1 quarter.
HAP Trading's Travere Therapeutics position peaked at $974K in Q1 2017.
108 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2017.

Based on HAP Trading's 13F filing for Q2 2017, filed 10 Aug 2017.